Johnson & Johnson (JNJ) Touts Its Pharma R&D Efforts for China  
5/28/2013 9:03:56 AM

by Richard Daverman, PhD

May 24, 2013 -- Janssen Pharmaceutical Companies, a division of Johnson & Johnson, did something this week that big pharmas haven't done very often in the last few years: it bragged about its recent drug discovery success and made predictions about its future progress. The company said it had four new medical entities awaiting approval in China along with four line extensions. It expects to file an additional nine NMEs and six line extensions for approval by 2017. More details....

Stock Symbol: (NYSE: JNJ)